Kazia Therapeutics Files 6-K Report

Ticker: KZIA · Form: 6-K · Filed: Feb 3, 2025 · CIK: 1075880

Kazia Therapeutics LTD 6-K Filing Summary
FieldDetail
CompanyKazia Therapeutics LTD (KZIA)
Form Type6-K
Filed DateFeb 3, 2025
Risk Levellow
Pages1
Reading Time1 min
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, foreign-private-issuer, pharmaceuticals

Related Tickers: KZA

TL;DR

Kazia Therapeutics (KZA) filed a routine 6-K, confirming its status as a foreign private issuer.

AI Summary

Kazia Therapeutics Limited, formerly Novogen Ltd, filed a Form 6-K on February 3, 2025. The company, headquartered in Sydney, NSW, is a pharmaceutical preparations company. This filing is a report of a foreign private issuer.

Why It Matters

This filing indicates ongoing reporting requirements for Kazia Therapeutics as a foreign private issuer, providing transparency to investors about its regulatory status.

Risk Assessment

Risk Level: low — This is a standard regulatory filing with no new material financial or operational information disclosed.

Key Numbers

Key Players & Entities

FAQ

What is the purpose of a Form 6-K filing?

A Form 6-K is a report of foreign private issuers required to be filed with the SEC to provide information that the issuer makes or is required to make public pursuant to the laws of its home country, or that is made or is required to be made available to its security holders.

When was Kazia Therapeutics Limited previously known as?

Kazia Therapeutics Limited was formerly known as Novogen Ltd, with a date of name change on 19981228.

What is Kazia Therapeutics Limited's Standard Industrial Classification (SIC) code?

Kazia Therapeutics Limited's SIC code is 2834, which corresponds to Pharmaceutical Preparations.

Where is Kazia Therapeutics Limited's principal executive office located?

The principal executive office of Kazia Therapeutics Limited is located at Three International Towers Level 24, 300 Barangaroo Avenue, Sydney NSW 2000.

Does Kazia Therapeutics Limited file annual reports under Form 20-F or 40-F?

Kazia Therapeutics Limited indicates it files annual reports under cover of Form 20-F.

Filing Stats: 227 words · 1 min read · ~1 pages · Grade level 15.1 · Accepted 2025-02-03 08:36:05

Filing Documents

From the Filing

6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of February, 2025 Commission File Number 000-29962 Kazia Therapeutics Limited (Translation of registrants name into English) Three International Towers Level 24 300 Barangaroo Avenue Sydney NSW 2000 (Address of principal executive office) Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F Form 40-F Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): INFORMATION CONTAINED IN THIS FORM 6-K REPORT On February 3, 2025, Kazia Therapeutics Limited (the Company) updated its corporate presentation for use in meetings with investors, analysts and others. A copy of the corporate presentation is attached hereto as Exhibit 99.1. EXHIBIT LIST Exhibit Description 99.1 Corporate Presentation SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Kazia Therapeutics Limited (Registrant) /s/ John Friend John Friend Chief Executive Officer Date: February 3, 2025

View Full Filing

View this 6-K filing on SEC EDGAR

View on Read The Filing